• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Sep 1, 2004; 114(5): 616–619.
PMCID: PMC514596

Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus

Abstract

Patients with systemic lupus erythematosus (SLE) often develop glomerulonephritis (i.e., inflammation in the glomeruli of the kidney), commonly referred to as lupus nephritis. Patients with lupus nephritis typically have autoantibodies to the complement classical pathway protein C1q. Whether these anti-C1q antibodies play any role in the development of lupus nephritis has been unclear. In this issue of the JCI, a new study demonstrates that anti-C1q antibodies can amplify glomerular injury but only when they are bound within the glomerulus to C1q that has been already brought to that site by other types of glomerular-reactive autoantibodies . These studies are the first, to our knowledge, to provide a causal link between anti-C1q antibodies and target organ damage in SLE.

The complement system is a central component of innate immunity that exhibits three pathways of activation: classical, alternative, and lectin-mediated. C1, a key component of the classical pathway, is actually a complex of three proteins: C1q, C1r, and C1s (1). C1q is a collagen-like component that is able to bind antibodies but only after the antibody has been bound to a foreign or self antigen. Once C1q is bound to the Fc antibody domain, C1r and C1s are sequentially cleaved and released, after which the rest of the classical pathway is activated. Immune complexes normally contain C1q bound via its “head” domains to Fc regions of IgG as part of the activation function of C1q within the classical pathway (1) (Figure (Figure1).1). An alternate means of binding C1q, though, has also been described; it occurs when high-affinity autoantibodies directly recognize the collagenous “tail” portion of C1q through the antibody F(ab) antigen-combining sites rather than via the Fc domain. Since they were first described (2, 3), anti-C1q autoantibodies have been commonly identified in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and hypocomplementemic urticarial vasculitis. Although anti-C1q antibodies are associated with the presence of lupus nephritis — indeed probably serving as a biomarker for the presence of renal disease (4) — and anti-C1q antibodies are also preferentially localized in the glomeruli of patients with SLE (5), their pathophysiologic importance has remained undefined. Specifically, whether this class of acquired autoantibodies is merely an epiphenomenon or is truly pathogenic, and if so how and under what clinical circumstances, has remained an unanswered question.

Figure 1
Roles of anti-C1q antibodies in the development of glomerular injury and antinuclear antibodies. (A) Anti-C1q antibodies (in yellow) such as JL-1 recognize the collagen-like “tails” of C1q in much the same manner as they would recognize ...

Anti-C1q autoantibodies are pathogenic

In this issue of the JCI, Trouw et al. (6) have now solved an important piece of this puzzle by first developing a murine mAb, JL-1, which was identified by ELISA based on its ability to recognize the tail domain of mouse C1q. When anti-C1q JL-1 was administered alone, it was bound in the glomerulus to C1q, which is normally present there at low levels; however, this interaction was insufficient to induce significant glomerular damage (Figure (Figure1A).1A). However, when JL-1 was administered to mice in which C1q levels in the glomerulus were greatly elevated as a consequence of its interaction with other antibodies with specificity for glomerular antigens, mice then exhibited significant glomerular injury as shown by decreased renal function and elevated “leakage” of protein into the urine (6) (Figure (Figure11B).

The combination of the first glomerular-binding antibody and JL-1 caused glomerular injury in a complement C4–, C3–, and Fc–dependent manner, reflecting a key role of the classical pathway itself in the generation of C3a, C5a, and the membrane attack complex (MAC). These downstream complement activation fragments are key mediators of complement-catalyzed autoimmune renal injury (7) (Figure (Figure1B).1B). In the setting described by Trouw et al., these complement mediators were probably generated by both types of antibodies, the initial glomerular-targeting antibodies as well as mAb JL-1. Together, the two types of antibodies generated enough mediators to be clinically important and cause glomerular injury in vivo. What do these results tell us about the role of C1q in SLE and also about this intriguing class of acquired autoantibodies?

First, one has to ask whether the lone monoclonal antibody, JL-1, utilized in this study (6) to amplify glomerular injury is representative of the polyclonal population of C1q-reactive antibodies in human patients. It could be argued, as is well known in murine models, that placement of a “planted antigen” (herein possibly C1q) in the glomerulus followed by administration of a complement-fixing antibody that targets the antigen in situ readily leads to complement-dependent injury (8). The model system utilized by Trouw et al. (6) simply recapitulates this phenotype but in a clinically unrelated fashion. In addition, as pointed out by the authors, previous experiments in mice using glomerular-targeting antibodies also demonstrate dose-dependent “windows,” in which the injurious effects of complement activation are more prominent than at higher or lower doses of antibody (9). In this light, the use by the authors of a broad range of doses (of each reagent, the C1q-fixing anti-glomerular basement membrane antibody, and JL-1) would show how narrow the effect of the addition of monoclonal anti-C1q antibody on the development of glomerular injury is.

However, in support of a close relationship between these findings in mice and SLE-associated lupus nephritis in humans, JL-1 is reported to recognize the same collagen-like domain of C1q as do human anti-C1q antibodies (2, 3, 6). In addition, previous studies in which C1q and polyclonal anti-C1q antibodies were both transferred into mice resulted in glomerular targeting of anti-C1q antibodies (10) as well as modest glomerular damage (11) similar to that caused by mAb JL-1 alone in the study by Trouw et al. (6). Nevertheless, a stronger link with human disease may be provided by a more careful comparison of the specific epitope reactivity of JL-1 and authentic autoantibodies from patients with glomerulonephritis. For example, is there evidence of cross-competition for C1q epitopes between human polyclonal anti-C1q autoantibodies and JL-1?

Anti-C1q antibodies increase complement activation in a relatively uncontrolled fashion

The complement system itself is regulated positively by amplification mechanisms (12) and negatively by regulatory proteins (13). At each activation step, a small amount of activated product can lead to the generation of from four to several thousand activated components derived from the immediate downstream target (1). The alternative pathway demonstrates an “amplification loop” effect, where C3b generated from the classical pathway can serve to bind factor B and initiate further C3 activation through formation of the C3 convertase C3bBb (12) (Figure (Figure2).2). Although often thought of as a minor contributor to total complement activation — which is true if one considers only serum activation — amplification of injury in a target organ through engagement of the alternative pathway, amplifying injury in a target organ, is absolutely essential to the generation of local C5a- and MAC-dependent injury (14, 15).

Figure 2
Simplified schematic demonstrating mechanisms of activation of classical and alternative pathways and generation of C3 convertases (light blue). The alternative pathway C3 convertase (green box) can be generated by the activity of the classical pathway ...

This concept is relevant to anti-C1q antibodies because the studies of Trouw et al. (6) strongly suggest that these autoantibodies likewise serve as an acquired mechanism of classical pathway amplification. Previously, the only means to amplify the classical pathway beyond what is possible through endogenous classical pathway components has been with C4-nephritic factor. This type of autoantibody, occasionally found in patients, stabilizes the classical pathway C3 convertase C4b2a and allows this convertase to generate far more activated C3 molecules than it normally would (16). Trouw et al. demonstrate that anti-C1q autoantibodies can result in a similarly amplified biologic effect of complement in vivo locally in the kidney, presumably by generating additional C3 through the classical pathway. In this light, it would be of some interest to determine the exact mechanism by which the classical pathway is amplified by JL-1 and whether this antibody interferes with other classical pathway regulatory mechanisms.

Additional deleterious roles potentially played by anti-C1q autoantibodies

In the larger context of lupus-like autoimmunity, C1q has taken on an increasingly important role and is necessary not only for classical pathway–dependent complement activation in target organs, as focused upon by Trouw et al. in this issue (6), but is also required to directly recognize and help to clear potentially dangerous nuclear autoantigens from apoptotic cells (17). Thus, in patients (18) and in certain autoimmune mouse strains (19), the absence of C1q leads to the development of anti-DNA antibodies and SLE. Of interest, C1q-deficient patients commonly exhibit severe renal disease (18), the cause of which has been ascribed to non–complement-dependent mechanisms, as C3 is not required in mice to develop glomerular injury in the absence of C1q (20).

In this context of multiple roles for C1q, one could hypothesize that anti-C1q autoantibodies not only affect patients with SLE by injuring the kidney, as suggested by Trouw et al. (6), but also by enhancing the development of anti-DNA and other glomerular-targeting nuclear autoantibodies, because there is too little C1q available for effective clearance of these dangerous antigens (Figure (Figure1C).1C). Thus, these autoantibodies would not only amplify local injury but also potentially accelerate the development of antinuclear autoantibodies by interfering with C1q clearance functions (21). Alternatively, if these autoantibodies also lead to enhanced complement activation at sites where C1q is recognizing nuclear antigens, this could in principle switch noninflammatory recognition of apoptotic bodies by C1q and its receptors to inflammatory recognition when C5a and other complement activation fragments are also generated, and their receptors are engaged on cells clearing these antigens.

In sum, acquired anti-C1q autoantibodies could utilize several possible mechanisms by which they could increase the severity of an autoimmune response and glomerulonephritis. The studies by Trouw et al. (6) provide an important conceptual advance in this area and open up the possibility of determining how inhibiting C1q or modulating its effects leads to severe SLE. In particular, the use of JL-1 and similar monoclonal antibodies in mouse models should allow these and other investigators to better understand the molecular mechanisms that lead both to increased development of anti-DNA antibodies and to tissue injury.

Footnotes

See the related article beginning on page 679.

Nonstandard abbreviations used: MAC, membrane attack complex; SLE, systemic lupus erythematosus.

Conflict of interest: The author has declared that no conflict of interest exists.

References

1. Lachmann PJ, Hughes-Jones NC. Initiation of complement activation. Springer Semin. Immunopathol. 1984;7:143–162. [PubMed]
2. Uwatoko S, Mannik M. Low-molecular weight C1q-binding immunoglobulin G in patients with systemic lupus erythematosus consists of autoantibodies to the collagen-like region of C1q. J. Clin. Invest. 1988;82:816–824. [PMC free article] [PubMed]
3. Wisnieski JJ, Naff GB. Serum IgG antibodies to C1q in hypocomplementemic urticarial vasculitis syndrome. Arthritis Rheum. 1989;32:1119–1127. [PubMed]
4. Coremans IEM, et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am. J. Kidney Dis. 1995;26:595–601. [PubMed]
5. Mannik M, Wener MH. Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 1997;40:1504–1511. [PubMed]
6. Trouw LA, et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J. Clin. Invest. 2004;114:679–688.doi:10.1172/JCI200421075. [PMC free article] [PubMed]
7. Quigg RJ. Complement and autoimmune glomerular diseases. Curr. Dir. Autoimmun. 2004;7:165–180. [PubMed]
8. Feintzeig ID, Dittmer JE, Cybulski AV, Salant DJ. Antibody, antigen, and glomerular capillary wall charge interactions: influence of antigen location on in situ immune complex formation. Kidney Int. 1986;29:649–657. [PubMed]
9. Quigg RJ, et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J. Immunol. 1998;160:4553–4560. [PubMed]
10. Uwatoko S, Gauthier VJ, Mannik M. Autoantibodies to the collagen-like region of C1Q deposit in glomeruli via C1Q in immune deposits. Clin. Immunol. Immunopathol. 1991;61:268–273. [PubMed]
11. Trouw LA, et al. Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. Clin. Exp. Immunol. 2003;132:32–39. [PMC free article] [PubMed]
12. Muller-Eberhard HJ. Molecular organization and function of the complement system. Ann. Rev. Biochem. 1988;57:321–347. [PubMed]
13. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv. Immunol. 1996;61:201–283. [PubMed]
14. Girardi G, et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J. Clin. Invest. 2003;112:1644–1654. doi:10.1172/JCI200318817. [PMC free article] [PubMed]
15. Holers VM, Thurman JM. The alternative pathway of complement in disease: opportunities for therapeutic targeting. Mol. Immunol. 2004;41:147–152. [PubMed]
16. Gigli I, Sorvillo J, Mecarelli-Halbwachs L, Leibowitch J. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase. J. Exp. Med. 1981;154:1–12. [PMC free article] [PubMed]
17. Botto M, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998;19:56–59. [PubMed]
18. Bowness P, et al. Hereditary C1q deficiency and systemic lupus erythematosus. Q. J. Med. 1994;87:455–464. [PubMed]
19. Mitchell DA, et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J. Immunol. 2002;168:2538–2543. [PubMed]
20. Mitchell DA, et al. C1q protects against the development of glomerulonephritis independently of C3 activation. J. Immunol. 1999;162:5676–5679. [PubMed]
21. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology. 2002;205:395–406. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...